Instanosis Inc.
Wynnewood, PA
- UEI
- CA5GQKREPCE4
- CAGE
- 8FF55
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 909 Honeysuckle Ln, Wynnewood, PA 19096, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | -$697,737 |
Contract awards
Grant awards
Similar vendors
About the company
Instanosis Inc. is a woman-owned small business based in Wynnewood, Pennsylvania, registered in SAM.gov and focused on developing advanced diagnostic technologies. The company specializes in creating rapid, sensitive, and innovative diagnostic testing platforms, with a primary emphasis on drug detection and medical screening technologies. Instanosis Inc. appears to be a research-driven organization that develops point-of-care and over-the-counter diagnostic tools, leveraging advanced technologies like microbubbling and lateral flow assays to address critical healthcare challenges.
Through its federal contract work, Instanosis Inc. has demonstrated capabilities in developing diagnostic technologies, as evidenced by its $50,000 contract with the Office of the Assistant Secretary for Preparedness and Response. The contract focused on developing an at-home microbubbling SARS-CoV-2 antigen test, indicating the company's expertise in creating innovative diagnostic solutions for emerging health threats. The contract was not set aside for any specific business type and represented a definitive contract for enabling home-based diagnostic technologies.
Instanosis Inc. has been highly active in federal grant awards, primarily through the National Institute on Drug Abuse (NIDA), focusing on developing rapid diagnostic tests for detecting various drugs, particularly in the context of the opioid epidemic. The company has received multiple grants to develop innovative screening technologies for fentanyl and xylazine detection, including oral fluid, saliva, and urine-based tests. These grants, totaling several million dollars, aim to create rapid, sensitive, and instrument-free diagnostic tools with potential FDA clearance. The grants also demonstrate Instanosis Inc.'s commitment to addressing emerging drug threats by developing highly sensitive testing methods that can be used in various clinical and public health settings, such as emergency departments, first response vehicles, and drug treatment clinics.
Quick answers
Is Instanosis Inc. registered in SAM.gov?
Yes. Instanosis Inc.'s SAM.gov registration is active through October 5, 2027.
What is Instanosis Inc.'s most recent federal award?
Instanosis Inc.'s most recent federal grant award is A rapid, sensitive and instrument-free oral fluid fentanyl test (R44DA061963), from National Institute on Drug Abuse (NIH), on June 15, 2025.
On GovTribe
See Instanosis Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors